ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1587

Oxidized Human Serum Albumin Is Increased in Systemic Lupus Erythematosus, but Not in Rheumatoid Arthritis

Hideto Takada1, Keiko Yasukawa 2, Suguru Honda 1, Masako Majima 1, Naoko Konda 1, Yasuhiro Katsumata 1, Michi Tsutsumino 1, Yutaka Yatomi 3 and Masayoshi Harigai 1, 1Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Department of Clinical Laboratory, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan, 3Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are at high risk of atherosclerosis and have high mortality due to cardiovascular disease. Oxidative stress is involved in the progression of atherosclerosis, with the percentage of human non-mercaptoalbumin (HNA%), the oxidized form of human serum albumin, attracting considerable attention as a potential biomarker of oxidative stress. Although previous studies have shown increased HNA% in the elderly people and in patients with either chronic kidney disease, diabetes mellitus, or liver cirrhosis, there are no reports on HNA% in patients with rheumatic diseases. The aim of this study was to evaluate HNA% in patients with SLE or RA and to identify factors associated with this biomarker.

Methods: We measured HNA% in patients with SLE, RA, and healthy controls by using high-performance liquid chromatography. Analysis of covariance was used to compare HNA% between SLE and healthy controls, or RA and healthy controls. Factors associated with HNA% in SLE and RA patients were assessed by using multiple linear regression analysis.

Results: HNA% was measured in 89 SLE patients [age (mean ± SD), 44 ± 11 years; female, 97%], 51 RA patients [age (mean ± SD), 62 ± 13 years; female, 94%], and 65 healthy controls [age (mean ± SD), 55 ± 14 years; female, 58%)]. All participants were Japanese. Mean HNA% (SD) of SLE, RA, and healthy controls were 23.0% (5.0%), 23.7% (4.7%), and 21.8% (3.7%), respectively. The correlation between HNA% and age was significant in RA patients and healthy controls, but not in SLE patients (Figure 1). The age-adjusted mean difference in HNA% between the SLE patients and the healthy controls was 2.9% (95% CI, 0.96 to 4.9%; Bonferroni corrected p value = 0.001), and between the RA patients and the healthy controls, 0.84% (95% CI, −3.0 to 1.3%; Bonferroni corrected p value=1.0), respectively. In SLE patients, SLICC/ACR damage index (β=0.48, p< 0.001) and serum creatinine level (β=0.24, p=0.01) were significantly associated with HNA%. In RA patients, serum creatinine level (β=0.42, p< 0.001), age (β=0.37, p=0.002), and daily prednisolone dosage (β=0.29, p=0.006) were significantly associated with HNA%.

Conclusion: SLE patients have increased HNA% compared to the healthy controls, especially in association with the SLICC/ACR damage index. Patients with RA do not show this association. In SLE patients, increased HNA% might reflect excessive oxidative stress and possibly be associated with an increased risk of atherosclerosis.


ACR_figure

Figure 1. Correlation between HNA% and age -A- in SLE patients, -B- in RA patients, -C- healthy controls. The correlation was examined by calculating Spearman’s rank correlation coefficients.


Disclosure: H. Takada, None; K. Yasukawa, None; S. Honda, None; M. Majima, None; N. Konda, None; Y. Katsumata, None; M. Tsutsumino, None; Y. Yatomi, None; M. Harigai, AbbVie Japan GK, 2, 8, Ayumi Pharmaceutical Co. Ltd., 2, Bristol Meyers Squib, 2, 5, 8, Bristol-Myers Squibb Co. Ltd, 2, 5, 8, Chugai Pharmaceutical Co. Ltd., 2, 5, 8, Chugai Pharmaceutical Co., Ltd., 2, 5, 8, Eisai Co. Ltd., 2, Eisai Co., Ltd., 2, Eli Lilly, 5, 8, Mitsubishi Tanabe Pharma Co., 2, Mitsubishi Tanabe Pharma Corp., 2, Nippon Kayaku Co. Ltd., 2, Taisho Toyama Pharmaceutical Co. Ltd., 2, Takeda Pharmaceutical Co., 2, Takeda Pharmaceutical Co., Ltd., 2, Teijin Pharma Ltd., 2, 8, Teijin Pharma, Ltd., 2, 8.

To cite this abstract in AMA style:

Takada H, Yasukawa K, Honda S, Majima M, Konda N, Katsumata Y, Tsutsumino M, Yatomi Y, Harigai M. Oxidized Human Serum Albumin Is Increased in Systemic Lupus Erythematosus, but Not in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/oxidized-human-serum-albumin-is-increased-in-systemic-lupus-erythematosus-but-not-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oxidized-human-serum-albumin-is-increased-in-systemic-lupus-erythematosus-but-not-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology